Furthermore, Novo Nordisk should earn important label expansions for some of its current medicines while developing new ones in other areas. Semaglutide is being tested in Alzheimer's disease. And the ...

Novo Nordisk, maker of Ozempic, applied for FDA approval for a weight loss pill, less than a week after rival Eli Lilly's clinical trial success.

Novo Nordisk now has an Ozempic pill. Citing a Novo spokesperson, pharmaceuticals news site BioPharmaDive reported yesterday ...

Almost unarguably, the most significant story in our time with the pharmaceutical industry is the emergence and sharp rise of GLP-1 obesity drugs. Front and center of this is Novo Nordisk (NYSE: NVO), ...

Novo Nordisk filed for approval of an oral, 25-mg formulation of semaglutide “earlier this year,” according to a company spokesperson.

While much of the recent GLP-1 saga has been written in the U.S., Novo Nordisk continues to expand its semaglutide empire across the globe and make inroads into large markets like Brazil.

Selskabet Novo Nordisk vil ikke have fagforeninger ind på ... Michael Hallgren, til TV 2 Fyn. Men den køber 3F ikke. - Vi bliver lukket ind på ni ud af ti arbejdspladser, og Novos arbejdsplads ...

Also Read: Novo Nordisk To Pay Around $2 Billion For Obesity Drug From China-Based Biotech The trial also demonstrated superiority to placebo for all confirmatory secondary outcomes assessed ...

Novo Nordisk produces most of their drugs in Europe, which could make them subject to tariffs and margin pressures. Also, Cagrisema, their drug in Phase 2 development, achieved 22.7% of weight ...

Its P/S ratio [TTM] is 8.19x, which is 139.4% higher than the sector median but 54.2% lower than its 5-year average. Novo Nordisk has beaten Wall Street's revenue estimates in eight of the last ...

29 March 2025 – Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus ® (oral semaglutide) significantly reduced the risk of major ...

which is already approved for Type 2 diabetes, at the American College of Cardiology's Annual Scientific Session in Chicago. Novo Nordisk has already applied in the U.S. and EU to expand the ...